Search results
Showing 106 to 120 of 168 results for fibrosis
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041
assessment and monitoring of changes in pulmonary status in people with cystic fibrosis? Any explanatory notes(if applicable) Why this...
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)
This guidance has been updated and replaced by NICE technology appraisal guidance 504.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)
This advice has been updated and replaced by NICE healthtech guidance 682.
Liver disease:- Should all children with meconium ileus receive ursodeoxycholic acid from diagnosis?
mortality in people with cystic fibrosis, and around 10 to 30% of people with cystic fibrosis will develop...
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)
We have moved Diagnostics guidance 48 to become HealthTech guidance 682. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
Discontinued Reference number: GID-TA10277
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.